23 Jul, 2026
According to Straits Research, the global anal cancer market size was valued at $0.95 billion in 2025 and is projected to grow from $1.01 billion in 2026 to $1.71 billion by 2034, at a CAGR of 6.73% during the forecast period 2026–2034.
Anal cancer, which affects the anal canal, a narrow channel situated at the distal end of the rectum through which stool passes, is a rare variety of cancer. The anal canal is located in the anal region, posterior to the rectum. Squamous cell carcinomas, the predominant form of anal cancer, originate from the squamous cells that line the anus. Anal cancer risk factors include exposure to specific strains of the human papillomavirus (HPV), diminished immune system function, and participation in receptive anal intercourse.
Furthermore, smoking and a prior history of certain sexually transmitted infections (STIs) can significantly increase the risk. The presence of anal bleeding, anal discomfort or pressure, discharge or itching, changes in bowel habits, and the formation of masses or tumors in the vicinity of the anus distinguishes anal cancer.
Globally, the incidence of anal cancer has surged dramatically. The global incidence of anal cancer in 2020 was documented to be 50,865 cases, as reported by GLOBOCAN. Similarly, the American Cancer Society estimates that the lifetime incidence rate of anal cancer is approximately 1 in 500. Moreover, there has been a documented rising trend in the annual incidence of mortality linked to anal cancer. For instance, GLOBOCAN reported that 19,293 people passed away from anal cancer in 2020.
Certain individuals are more susceptible to developing anal cancer due to the presence of particular risk factors. The human papillomavirus typically brings on squamous cell anal cancers. Infection with the human papillomavirus (HPV) accounts for approximately 5% of all cancer cases worldwide. An estimated 625,600 females and 69,400 males are diagnosed with cancer each year as a result of HPV infection. The increasing prevalence of risk factors consequently elevates the likelihood of developing anal cancers, a factor that is anticipated to propel the worldwide anal cancer market.
Ongoing clinical trials and research studies that contribute to the development of new drugs and treatment approaches for anal cancer have increased in number. Kharofa, in collaboration with Ride Cincinnati, a non-profit bike organization dedicated to cancer research and care, commenced a clinical trial in September 2023. The primary objective of this trial is to mitigate medication adverse effects and enhance prognoses for patients diagnosed with anal cancer. The objective of this study is to determine whether a reduction in the dose of radiation delivered to a healthy lymph node in a patient diagnosed with anal cancer results in an amelioration of adverse effects.
After completing treatment, cancer patients enrolled at the University of California, Ohio State University, Case Western University, and the University of Vermont may continue to participate in the study for a maximum of three years. Positive findings derived from these studies have the potential to generate opportunities for market expansion.
North America is the most significant global anal cancer market shareholder and is expected to expand substantially during the forecast period. The North American anal cancer market is mainly boosted by the increasing prevalence of anal cancer in the region. For instance, in the United States, the number of new anal cancer cases has been increasing over the past several years. The American Cancer Society projects that approximately 9,760 adults in the United States will be diagnosed with anal cancer in 2023 (3,180 men and 6,580 women). An approximate total of 1,870 fatalities (860 male and 1,010 female) are attributed to this ailment within the United States in 2023.
The Asia-Pacific region is estimated to exhibit a significant rate. Increasing disposable income, improving healthcare infrastructure, and rising consumer awareness will likely be key market drivers in the Asia-Pacific region. The surging geriatric population in the region is further contributing to market expansion. For instance, according to the United Nations Economic and Social Commission for Asia-Pacific (ESCAP), The rate of population aging in the Asia-Pacific area surpasses that of any other global region. The global population comprises around 630 million individuals who are 60 or older, accounting for 60% of the total older population worldwide. According to projections, the global population is expected to reach 1.3 billion by 2050. Therefore, a surge in the geriatric population increases the risk of anal cancer, which is anticipated to boost the Asia-Pacific market.
sales@straitsresearch.com